PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
Malaysia rolled out a diverse portfolio of predominantly three COVID-19 vaccines (AZD1222, BNT162b2, and CoronaVac) beginning 24 February 2021. We evaluated vaccine effectiveness with two methods, covering 1 April to 15 September 2021: (1) the screening method for COVID-19 (SARS-CoV-2) infection and...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/12/1381 |
| _version_ | 1797500127308414976 |
|---|---|
| author | Jing Lian Suah Peter Seah Keng Tok Su Miin Ong Masliyana Husin Boon Hwa Tng Sheamini Sivasampu Thevesh Thevananthan Maheshwara Rao Appannan Faizah Muhamad Zin Shahanizan Mohd Zin Hazlina Yahaya Norhayati Rusli Mohd Fikri Ujang Hishamshah Mohd Ibrahim Noor Hisham Abdullah Kalaiarasu M. Peariasamy |
| author_facet | Jing Lian Suah Peter Seah Keng Tok Su Miin Ong Masliyana Husin Boon Hwa Tng Sheamini Sivasampu Thevesh Thevananthan Maheshwara Rao Appannan Faizah Muhamad Zin Shahanizan Mohd Zin Hazlina Yahaya Norhayati Rusli Mohd Fikri Ujang Hishamshah Mohd Ibrahim Noor Hisham Abdullah Kalaiarasu M. Peariasamy |
| author_sort | Jing Lian Suah |
| collection | DOAJ |
| description | Malaysia rolled out a diverse portfolio of predominantly three COVID-19 vaccines (AZD1222, BNT162b2, and CoronaVac) beginning 24 February 2021. We evaluated vaccine effectiveness with two methods, covering 1 April to 15 September 2021: (1) the screening method for COVID-19 (SARS-CoV-2) infection and symptomatic COVID-19; and (2) a retrospective cohort of confirmed COVID-19 cases for COVID-19 related ICU admission and death using logistic regression. The screening method estimated partial vaccination to be 48.8% effective (95% CI: 46.8, 50.7) against COVID-19 infection and 33.5% effective (95% CI: 31.6, 35.5) against symptomatic COVID-19. Full vaccination is estimated at 87.8% effective (95% CI: 85.8, 89.7) against COVID-19 infection and 85.4% effective (95% CI: 83.4, 87.3) against symptomatic COVID-19. Among the cohort of confirmed COVID-19 cases, partial vaccination with any of the three vaccines is estimated at 31.3% effective (95% CI: 28.5, 34.1) in preventing ICU admission, and 45.1% effective (95% CI: 42.6, 47.5) in preventing death. Full vaccination with any of the three vaccines is estimated at 79.1% effective (95% CI: 77.7, 80.4) in preventing ICU admission and 86.7% effective (95% CI: 85.7, 87.6) in preventing deaths. Our findings suggest that full vaccination with any of the three predominant vaccines (AZD1222, BNT162b2, and CoronaVac) in Malaysia has been highly effective in preventing COVID-19 infection, symptomatic COVID-19, COVID-19-related ICU admission, and death. |
| first_indexed | 2024-03-10T03:57:25Z |
| format | Article |
| id | doaj.art-cdbf934d627c445cb11606e647a8cff3 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T03:57:25Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-cdbf934d627c445cb11606e647a8cff32023-11-23T10:53:33ZengMDPI AGVaccines2076-393X2021-11-01912138110.3390/vaccines9121381PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine PortfolioJing Lian Suah0Peter Seah Keng Tok1Su Miin Ong2Masliyana Husin3Boon Hwa Tng4Sheamini Sivasampu5Thevesh Thevananthan6Maheshwara Rao Appannan7Faizah Muhamad Zin8Shahanizan Mohd Zin9Hazlina Yahaya10Norhayati Rusli11Mohd Fikri Ujang12Hishamshah Mohd Ibrahim13Noor Hisham Abdullah14Kalaiarasu M. Peariasamy15COVID-19 Immunisation Task Force, Government of Malaysia, Putrajaya 62000, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, MalaysiaCOVID-19 Immunisation Task Force, Government of Malaysia, Putrajaya 62000, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, MalaysiaCOVID-19 Immunisation Task Force, Government of Malaysia, Putrajaya 62000, MalaysiaDisease Control Division, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaMedical Development Division, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaMedical Development Division, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaDisease Control Division, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaDisease Control Division, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaMedical Development Division, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaOffice of Director-General, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaOffice of Director-General, Ministry of Health Malaysia, Putrajaya 62590, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, MalaysiaMalaysia rolled out a diverse portfolio of predominantly three COVID-19 vaccines (AZD1222, BNT162b2, and CoronaVac) beginning 24 February 2021. We evaluated vaccine effectiveness with two methods, covering 1 April to 15 September 2021: (1) the screening method for COVID-19 (SARS-CoV-2) infection and symptomatic COVID-19; and (2) a retrospective cohort of confirmed COVID-19 cases for COVID-19 related ICU admission and death using logistic regression. The screening method estimated partial vaccination to be 48.8% effective (95% CI: 46.8, 50.7) against COVID-19 infection and 33.5% effective (95% CI: 31.6, 35.5) against symptomatic COVID-19. Full vaccination is estimated at 87.8% effective (95% CI: 85.8, 89.7) against COVID-19 infection and 85.4% effective (95% CI: 83.4, 87.3) against symptomatic COVID-19. Among the cohort of confirmed COVID-19 cases, partial vaccination with any of the three vaccines is estimated at 31.3% effective (95% CI: 28.5, 34.1) in preventing ICU admission, and 45.1% effective (95% CI: 42.6, 47.5) in preventing death. Full vaccination with any of the three vaccines is estimated at 79.1% effective (95% CI: 77.7, 80.4) in preventing ICU admission and 86.7% effective (95% CI: 85.7, 87.6) in preventing deaths. Our findings suggest that full vaccination with any of the three predominant vaccines (AZD1222, BNT162b2, and CoronaVac) in Malaysia has been highly effective in preventing COVID-19 infection, symptomatic COVID-19, COVID-19-related ICU admission, and death.https://www.mdpi.com/2076-393X/9/12/1381COVID-19SARS-CoV-2COVID-19 vaccinesvaccine effectivenesscohort studyMalaysia |
| spellingShingle | Jing Lian Suah Peter Seah Keng Tok Su Miin Ong Masliyana Husin Boon Hwa Tng Sheamini Sivasampu Thevesh Thevananthan Maheshwara Rao Appannan Faizah Muhamad Zin Shahanizan Mohd Zin Hazlina Yahaya Norhayati Rusli Mohd Fikri Ujang Hishamshah Mohd Ibrahim Noor Hisham Abdullah Kalaiarasu M. Peariasamy PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio Vaccines COVID-19 SARS-CoV-2 COVID-19 vaccines vaccine effectiveness cohort study Malaysia |
| title | PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio |
| title_full | PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio |
| title_fullStr | PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio |
| title_full_unstemmed | PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio |
| title_short | PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio |
| title_sort | pick ing malaysia s epidemic apart effectiveness of a diverse covid 19 vaccine portfolio |
| topic | COVID-19 SARS-CoV-2 COVID-19 vaccines vaccine effectiveness cohort study Malaysia |
| url | https://www.mdpi.com/2076-393X/9/12/1381 |
| work_keys_str_mv | AT jingliansuah pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT peterseahkengtok pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT sumiinong pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT masliyanahusin pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT boonhwatng pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT sheaminisivasampu pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT theveshthevananthan pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT maheshwararaoappannan pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT faizahmuhamadzin pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT shahanizanmohdzin pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT hazlinayahaya pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT norhayatirusli pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT mohdfikriujang pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT hishamshahmohdibrahim pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT noorhishamabdullah pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio AT kalaiarasumpeariasamy pickingmalaysiasepidemicaparteffectivenessofadiversecovid19vaccineportfolio |